Begin your journey towards better sleep with eXciteOSA®

The first FDA authorized therapy that targets the root cause of mild obstructive sleep apnea (OSA) and snoring rather than simply relieving the symptoms.¹³

Daytime use for nighttime results

eXciteOSA® is the only daytime solution clinically proven to help with mild OSA and snoring. The non-invasive device only needs to be worn for 20 minutes a day, 1 time each day, for 6 weeks. Therapy is required only twice a week thereafter.

Clinically proven

- 90% of patients reported a reduction in snoring time³
- 89% of bed partners reported a reduction of their partners snoring³
- 79% of sleep apnea patients achieved a reduction in sleep apnea measures³

Easy to use

The smartphone app seamlessly connects to your eXciteOSA® device, making it easy to complete therapy sessions and track progress.

Why is sleep so important?

eXciteOSA® will help you do more than just sleep better. Quality of sleep is directly correlated with quality of daily life. The better you sleep, the more energized, healthy, and present you’ll be.
About the therapy

eXciteOSA® improves the muscle function of the tongue through stimulation therapy. Strengthening these muscles prevents the upper airway tissue from collapsing and trains the upper airway to remain open during sleep, thereby improving sleep quality.

How it works

• The eXciteOSA® mouthpiece gets positioned onto your tongue.

• The app activates and customizes each therapy session.

• The app tracks your progress and keeps you focused on therapy goals.

What to expect

• Each session includes four, 5-minute phases, each designed to train your tongue muscle in a different way.

• Therapy levels outside of your comfort zone will not improve outcome or speed up results.

• Some patients experience slight accumulation of saliva during their first few uses.

Questions? Email info@signifiermedical.com or call +1 844 MildOSA

eXciteOSA® is a registered trademark of Signifier Medical Technologies. ©2021 Signifier Medical Technologies. All rights reserved. EX0002 2/21